← Back to Search

18F-MK-6240 for Alzheimer's Disease

Phase 2
Waitlist Available
Led By William Kreisl, MD
Research Sponsored by William Charles Kreisl
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 50 and older.
Meet criteria for either
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to one year from screening.
Awards & highlights

Study Summary

This trial is measuring the amount of tau protein in the brain to see if it's linked to Alzheimer's disease.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one year from screening.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year from screening. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
18F-MK-6240 binding
Secondary outcome measures
Correlation between tau, neurodegeneration and inflammation using PET and CSF biomarkers.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive impairmentExperimental Treatment2 Interventions
Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
Group II: No cognitive impairmentActive Control2 Interventions
Healthy controls
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-MK-6240
2019
Completed Phase 2
~220
Lumbar Puncture (optional)
2017
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

William Charles KreislLead Sponsor
6 Previous Clinical Trials
481 Total Patients Enrolled
James M Noble, MD, MS, CPH, FAANLead Sponsor
2 Previous Clinical Trials
200 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,658 Previous Clinical Trials
28,004,374 Total Patients Enrolled

Frequently Asked Questions

~10 spots leftby Mar 2025